An observational study in Ulcerative Colitis and Inflammatory Bowel Diseases, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 239 studies in Colitis, Ulcerative with a site in France — 45 open to participants now, 78 under way, 27 of them phase 3. Colitis, Ulcerative · France.
Among the 239 studies in Colitis, Ulcerative with a site in France, this one is the 45th largest by planned enrollment of the 55 observational ones that give a count, is one of 15 that started in 2022, is one of 55 observational ones, reaches primary completion later than 41 of the 77 other live ones, and was the 167th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →45 of the 239 studies in Colitis, Ulcerative with a site in France are open now. Recruiting first, the newest first:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Palisade Bio · Sites in France, United States, Canada and 9 more countries
Ages 18–75
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 17
Pfizer · Sites in France, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in France, United States, Argentina and 30 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
239 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 71 · Phase 3 73 · Phase 4 14
First in 2003; this study’s year is marked. 15 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 95 is below the median of 199 across 552 observational studies indexed under Colitis, Ulcerative.
Median enrollment 196 across the 184 interventional studies, 360 across the 55 observational. Of the 151 that completed or were terminated, 71 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
149 of 239 have an industry lead sponsor. The 10 most frequent:
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
Central Hospital, Nancy, France has 8 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
21 of the studies in Colitis, Ulcerative with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 21 to your calendar (.ics) → With an account.
Among the 239 studies in Colitis, Ulcerative with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
UC is a chronic, idiopathic form of intestinal inflammatory disease (IBD) that affects the colon, most commonly afflicting adults aged 30-40 years and resulting in disability and lower quality of life (1). It is characterized by relapsing and remitting mucosal inflammation, starting in the rectum and extending to proximal segments of the colon. Although biologic therapies have provided clinical benefits to patients, these goals are still poorly met, due to the limited knowledge of the underlying mechanisms of immunopathology and the lack of predictive biomarkers that would allow proper patient stratification.
The hypothesis of this study is that by identifying new biomarkers in blood, stool and tissue that (i) predict response (or non-response) to therapy prior to the start of treatment and (ii) predict response to therapy in the early phase of treatment will allow to find the right treatment for the right patient (personalized medicine).
Patients with moderate to severe active UC with an indication to start a biologic treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Person referred in articles L.1121-5, L. 1121-7 and L.1121-8 of the Public Health Code:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients with an established ulcerative colitis
Procedure: Procedure: endoscopic biopsy · Procedure: Blood sampling · Procedure: stool sampling
Per-endoscopic biopsies
Blood sampling
stool sampling
The percentage of subjects who achieve clinical response at week 14.
Clinical response will be defined as overall Mayo score of 2 or smaller with Mayo endoscopy score (Mayo ES) of 0 or 1 (without friability), and bleeding subscore of 0. The Clinical Response will be categorized in four subcategories: * Super responder: meets criteria of clinical response * Responder: Mayo Score: reduction of 50%/ improvement of ≥ 3 from baseline, but does not meet criteria of remission; endoscopic Mayo: does not meet criteria of clinical response, but shows reduction of Mayo ES * Partial responder: Mayo Score: reduction of up to 30%, endoscopic Mayo: no formal improvement by Mayo ES but in overall assessment by the physician slight improvement. * Non-responder: reduction of less than 30% and in endoscopy no improvement in the overall assessment
Time frame: The percentage of subjects who achieve clinical response at week 14
The percentage of subjects who achieve deep clinical remission at week 14.
Deep clinical remission will be defined as partial Mayo Score 0-1 with stool frequency (SF) ≤1 and rectal bleeding (RB) = 0.
Time frame: The percentage of subjects who achieve deep clinical remission at week 14
The percentage of subjects who achieve deep clinical remission at week 26.
Deep clinical remission will be defined as partial Mayo Score 0-1 with stool frequency (SF) ≤1 and rectal bleeding (RB) = 0.
Time frame: The percentage of subjects who achieve deep clinical remission at week 26.
The percentage of subjects who achieve deep clinical remission at week 52.
Deep clinical remission will be defined as partial Mayo Score 0-1 with stool frequency (SF) ≤1 and rectal bleeding (RB) = 0.
Time frame: The percentage of subjects who achieve deep clinical remission at week 52.
The percentage of subjects who achieve mucosal healing at week 14.
Mucosal healing will be defined as Mayo endoscopic score = 0; Nancy histology index: ulceration: 0, neutrophils: 0, chronic infiltrate: 0 or 1.
Time frame: The percentage of subjects who achieve mucosal healing at week 14.
The percentage of subjects who achieve mucosal healing at week 52.
Mucosal healing will be defined as Mayo endoscopic score = 0; Nancy histology index: ulceration: 0, neutrophils: 0, chronic infiltrate: 0 or 1.
Time frame: The percentage of subjects who achieve mucosal healing at week 52.
The percentage of subjects who achieve symptomatic remission at week 14.
Symptomatic remission will be defined as reported by patient on PRO 2 (SF= 0-1 and RB= 0).
Time frame: The percentage of subjects who achieve symptomatic remission at week 14.
The percentage of subjects who achieve symptomatic remission at week 26.
Symptomatic remission will be defined as reported by patient on PRO 2 (SF= 0-1 and RB= 0).
Time frame: The percentage of subjects who achieve symptomatic remission at week 26.
The percentage of subjects who achieve symptomatic remission at week 52.
Symptomatic remission will be defined as reported by patient on PRO 2 (SF= 0-1 and RB= 0).
Time frame: The percentage of subjects who achieve symptomatic remission at week 52.
The percentage of subjects without any disease progression (e.g. flares) at week 14.
The percentage of subjects without any disease progression (e.g. flares) at week 14.
Time frame: The percentage of subjects without any disease progression (e.g. flares) at week 14.
The percentage of subjects without any disease progression (e.g. flares) at week 26.
The percentage of subjects without any disease progression (e.g. flares) at week 26.
Time frame: The percentage of subjects without any disease progression (e.g. flares) at week 26.
The percentage of subjects without any disease progression (e.g. flares) at week 52.
The percentage of subjects without any disease progression (e.g. flares) at week 52.
Time frame: The percentage of subjects without any disease progression (e.g. flares) at week 52.
The percentage of subjects who show an improvement on patient reported outcomes at week 14.
Patient reported outcomes include: PRO 2 (stool frequency (SF) and rectal bleeding (RB)), FACIT-F (level of fatigue), PROMIS Depression (level of depression), SF-36 (level of quality of life), Euro-QoL-5D (level of quality of life).
Time frame: The percentage of subjects who show an improvement on patient reported outcomes at week 14.
The percentage of subjects who show an improvement on patient reported outcomes at week 26.
Patient reported outcomes include: PRO 2 (stool frequency (SF) and rectal bleeding (RB)), FACIT-F (level of fatigue), PROMIS Depression (level of depression), SF-36 (level of quality of life), Euro-QoL-5D (level of quality of life).
Time frame: The percentage of subjects who show an improvement on patient reported outcomes at week 26.
The percentage of subjects who show an improvement on patient reported outcomes at week 52.
Patient reported outcomes include: PRO 2 (stool frequency (SF) and rectal bleeding (RB)), FACIT-F (level of fatigue), PROMIS Depression (level of depression), SF-36 (level of quality of life), Euro-QoL-5D (level of quality of life).
Time frame: The percentage of subjects who show an improvement on patient reported outcomes at week 52.
The percentage of subjects without the following complications until week 52 :
The percentage of subjects without the following complications until week 52: * hospitalizations due to UC * treatment intensification including introduction of toxic long-term therapies (i.e. systemic glucocorticoids) * new stenosis * new fistula * new development of primary sclerosing cholangitis (PSC) * infections * intestinal surgery
Time frame: week 52
The percentage of subjects without long-term complications until week 104.
The percentage of subjects without long-term complications until week 104.
Time frame: The percentage of subjects without long-term complications until week 104.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Sep 2027, 61 months after the start.
Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 61 months is above that.
Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →